HDAC9 and Miyoshi myopathy: For instance, HDAC4 is implicated in MM cell survival and migration, and panobinostat, a pan-HDAC inhibitor, in combination with a proteasome inhibitor and dexamethasone, has improved survival in relapsing and refractory MM patients (Imai et al., 2019).